Evotec announces Research Agreement on Fragment Based Screening Drug
Discovery with Cubist Pharmaceu
Evotec announces Research Agreement on Fragment Based Screening Drug Discovery with Cubist Pharmaceuticals
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Hamburg, Germany/ Oxford, UK - Evotec AG (Frankfurt Stock Exchange:EVT; NASDAQ: EVTC), a leading provider in the discovery anddevelopment of novel small molecule drugs, today announced that ithas entered into a research agreement with Cubist Pharmaceuticals,Inc. (NASDAQ: CBST), a leading acute care biopharmaceutical companylocated in Lexington, Mass., USA.Cubist will use Evotec's proprietary fragment screening technology,EVOlutionTM to complement discovery research efforts in two of itsantibacterials programs. EVOlutionTM combines biochemical, nuclearmagnetic resonance (NMR) and surface plasmon resonance (SPR)screening technologies for the screening of low molecular weightcompounds and fragments. By the combination of the orthogonalscreening technologies, Evotec's fragment screening platform iscapable of screening a more diverse set of biological targets thanother fragment screening approaches, as well as being able to screenthe fragments in a high-throughput mode. The benefit of this is theability to identify active fragments for numerous classes ofbiological targets in a short space of time.In combination with fragment screening technology, Evotec will useits expertise in structural biology and protein crystallography inorder to determine the 3-dimensional structure of the fragments boundto the targets of interest. To this end, Evotec will use itsinternal crystallography platform and will access thestate-of-the-art synchrotron technology of the Diamond Light Source,its partner for protein crystallography. By providing thistechnology in combination with its fragment screening, Evotec willsupply high quality results to Cubist to enable the structure-drivenidentification of drug candidates for their priority antibacterialtargets.Dr Mark Ashton, Evotec's EVP, Business Development commented: "We arepleased to be working with Cubist and look forward to identifyinginteresting fragments for their targets and to supporting them intheir quest for new treatments for antibacterial diseases."No financial details are disclosed.About fragment-based drug discoveryFragment-based drug discovery (FBDD) is a new paradigm in drugdiscovery that utilizes very small molecules - fragments of morecomplex molecules - to generate efficient starting points for drugdiscovery. This approach thus provides the opportunity to effectivelymanage the molecular weight and overall complexity of drugcandidates, a recognised success factor in drug development.About NMR and SPR screening technologiesNMR and SPR screening technologies are used to study the interactionof small molecules, such as drug candidates, with their targets.About Diamond Light SourceDiamond generates extremely intense pin-point beams of synchrotronlight of exceptional quality ranging from x-rays, ultra-violet andinfrared. For example Diamond's x-rays are around 100 billion timesbrighter than a standard hospital X-ray machine or 10 billion timesbrighter than the sun. For more information about Diamond, seewww.diamond.ac.ukFor further information, please contact:Dr Mark AshtonEVP, Business DevelopmentEvotec AGT: +44 (0) 1235 441236E : mark.ashton(at)evotec.comKaren SlackDe Facto CommunicationsT : +44 (0) 20 7861 3043E : k.slack(at)defacto.comForward-Looking StatementsInformation set forth in this press release contains forward-lookingstatements, which involve a number of risks and uncertainties. Suchforward-looking statements include, but are not limited to,statements about our expectations and assumptions concerningregulatory, clinical and business strategies, the progress of ourclinical development programs and timing of the results of ourclinical trials, strategic collaborations and management's plans,objectives and strategies. These statements are neither promises norguarantees, but are subject to a variety of risks and uncertainties,many of which are beyond our control, and which could cause actualresults to differ materially from those contemplated in theseforward-looking statements. In particular, the risks anduncertainties include, among other things: risks that the Company maybe unable to reduce its cash burn through recent restructuring andcost containment measures; risks that product candidates may fail inthe clinic or may not be successfully marketed or manufactured; risksrelating to our ability to advance the development of productcandidates currently in the pipeline or in clinical trials; ourinability to further identify, develop and achieve commercial successfor new products and technologies; the risk that competing productsmay be more successful; our inability to interest potential partnersin our technologies and products; our inability to achieve commercialsuccess for our products and technologies; our inability to protectour intellectual property and the cost of enforcing or defending ourintellectual property rights; our failure to comply with regulationsrelating to our products and product candidates, including FDArequirements; the risk that the FDA may interpret the results of ourstudies differently than we have; the risk that clinical trials maynot result in marketable products; the risk that we may be unable tosuccessfully secure regulatory approval of and market our drugcandidates; and risks of new, changing and competitive technologiesand regulations in the U.S. and internationally.The list of risks above is not exhaustive. Our most recent AnnualReport on Form 20-F, filed with the Securities and ExchangeCommission, and other documents filed with, or furnished to theSecurities and Exchange Commission, contain additional factors thatcould impact our businesses and financial performance. We expresslydisclaim any obligation or undertaking to release publicly anyupdates or revisions to any such statements to reflect any change inour expectations or any change in events, conditions or circumstanceson which any such statement is based.http://hugin.info/131215/R/1328615/313293.pdf --- End of Message ---Evotec AGSchnackenburgallee 114 Hamburg GermanyWKN: 566480; ISIN: DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt in Frankfurter Wertpapierbörse;
" alt="Update after the end of Q2 2009>">
" alt="Metro International signs joint venture and franchise agreement in
Ecuador>">
Datum: 14.07.2009 - 08:58 Uhr
Sprache: Deutsch
News-ID 3531
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Evotec announces Research Agreement on Fragment Based Screening Drug
Discovery with Cubist Pharmaceu"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
